valbenazine valbenazine valbenazine, sold under the trade name ingrezza, is a medication used to treat tardive dyskinesia. it acts as a vesicular monoamine transporter 2 (vmat2) inhibitor. valbenazineclinical datatrade namesingrezzaother namesnbi-98854ahfs/drugs.comingrezzaroutes ofadministrationby mouthatc coden07xx13 (who) legal statuslegal status us: ℞-only pharmacokinetic dataprotein binding>99%metabolismactivation by hydrolysis, deactivation by cyp3a, cyp2d6metabolites-α-dihydrotetrabenazine (active metabolite)elimination half-life15–22 hrsexcretion60% urine, 30% faecesidentifiers iupac name (2r,3r,11br)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyridoisoquinolin-2-yl l-valinate cas number1025504-45-3 ypubchem cid24795069drugbankdb11915 ychemspider28536134 yunii54k37p50khkeggd10675 yas salt: d10999 ychemblchembl2364639 yecha infocard100.236.234 chemical and physical dataformulac24h38n2o4molar mass418.578 g·mol−13d model (jsmol)interactive image smiles cc(c)c1cn2ccc3cc(c(cc32c1oc(=o)(c(c)c)n)oc)oc inchi inchi=inchi=1s/c24h38n2o4/c1-14(2)9-17-13-26-8-7-16-10-21(28-5)22(29-6)11-18(16)19(26)12-20(17)30-24(27)23(25)15(3)4/h10-11,14-15,17,19-20,23h,7-9,12-13,25h2,1-6h3/t17-,19-,20-,23+/m1/s1 ykey:gejdgvnqkabxkg-cfkgezkqsa-n y medical use valbenazine is used to treat tardive dyskinesia in adults. tardive dyskinesia is a drug-induced neurological injury characterized by involuntary movements. the clinical trials that led to fda approval of valbenazine were 6 weeks in duration. an industry-sponsored study has studied the use of valbenazine for up to 48 weeks, in which it was found to be safe and effective for maintaining short-term (6 week) improvements in tardive dyskinesia. contraindications there are no contraindications for the use of valbenazine according to the prescribing information. valbenazine has not been effectively studied in pregnancy, and it is recommended that women who are pregnant or breastfeeding avoid use of valbenazine. adverse effects side effects may include sleepiness or qt prolongation. significant prolongation has not yet been observed at recommended dosage levels, however, those taking inhibitors of the liver enzymes cyp2d6 or cyp3a4 – or who are poor cyp2d6 metabolizers – may be at risk for significant prolongation. pharmacology mechanism of action